news
Engineered stem cells could evade immune system rejection, study shows
By editing out a set of proteins on the surface of human pluripotent stem cells, researchers have ensured they will be not be rejected by the body's immune system.
List view / Grid view
Protein
news
Stem cells used to identify potential treatments for Parkinson’s disease
Scientists have found two active substances that allowed cells to reactivate the production of a protein that prevents the onset of Parkinson's disease.
article
Exploring the intra-protein non-covalent interactions in the S1 domain of the SARS-CoV-2 S1 Spike protein
The Spike (S) protein is a promising drug target in the quest to develop vaccines and antivirals for SARS-CoV-2 to treat and prevent COVID-19. Intra-protein interaction energy landscape mapping efforts have recently identified key interactions that may be crucial for the S protein’s ability to bind to receptor proteins on…
article
Adding to the arsenal: targeting human proteins for controlling M. tuberculosis growth
The National Institute of Health envisions a plan for managing tuberculosis in the 21st century. Included in this proposal is targeting host proteins as an add-on therapy to antibiotics. Infectious disease biologists are focusing on this strategy and it is a topic of active research. Recently, a multinational research team…
article
Under the microscope: Transforming drug discovery on membrane proteins
IN NOVEMBER 2017, leadXpro chose to strengthen its capabilities with the Creoptix™ WAVEsystem. “We were looking for a label‑free, biophysical method to investigate binding affinity and kinetics of small molecules with challenging integral membrane proteins,” explained Michael Hennig, Chief Executive Officer of leadXpro.
news
Concanamycin A antibiotic that targets Nef protein could cure HIV
Researchers have revealed that the antibiotic concanamycin A targets a protein called Nef, allowing the immune system to destroy HIV in cells.
article
Bispecific antibodies: the next generation of immuno-oncology drugs
Taylor B Guo, Chief Scientific Officer at I-Mab, describes the potential benefits of bispecific antibodies for cancer therapy and how their dual targeting mechanisms of action may drive their emergence as the next generation of immuno-oncology drugs.
article
Antibody therapeutics for COVID-19
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
article
Assays In-Depth Focus 2020
In this In-Depth Focus find articles exploring the roles of key proteins implicated in Alzheimer's disease and a new technology enabling the identification of novel cancer biomarkers.
article
Targets In-Depth Focus 2020
This in-depth focus includes articles on the importance of a novel target to treat M. tuberculosis infections and how recently identified interactions between the SARS-CoV-2 Spike protein and host epithelial cells could be used in the development of COVID-19 therapeutics.
news
Genetic analysis reveals disease-causing protein drug targets
An analysis of blood protein levels has supported drug target prioritisation by identifying the causal effects of proteins on diseases, a team has shown.
article
Drug Target Review – Issue 3 2020
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…
news
Astrocytes likely contribute to Parkinson’s disease progression
A new study shows astrocytes derived from monogenic Parkinson’s patients have metabolic alterations that mean they could be contributing to disease progression.
article
Innovations for next-generation antibody-drug conjugates
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
news
Engineered protein could be used to treat type 2 diabetes
An engineered form of the SMOC1 protein has shown success as a type 2 diabetes treatment in animal models, say researchers.
